Philip Stephen Wells
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Philip Stephen Wells has a total of 353 co-authors. Here are the top co-authors by number of shared publications:
- Marc Carrier
Department of Medicine University of Ottawa at The Ottawa Hospital Ottawa Ontario Canada
8 shared publications Marc Carrier
Department of Medicine, University of Ottawa, Ottawa, Canada; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada
6 shared publications- Frederikus Albertus Klok
Department of Medicine-Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands
5 shared publications - Marc Alan Rodger
Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
5 shared publications Ranjeeta Mallick
Method Center The Ottawa Hospital Research Institute Ottawa Ontario Canada
5 shared publications- Anthonie W. A. Lensing
Bayer AG, Wuppertal, Germany
4 shared publications
Latest Publications
- Open Access
- 25 October 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (11)
Efficacy and Safety of Apixaban Thromboprophylaxis According to Baseline Chemotherapy Class in High‐Risk Ambulatory Cancer Patients: A Post Hoc Analysis of the AVERT Trial
Background: Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in cancer patients. The AVERT trial showed apixaban thromboprophylaxis reduced VTE in intermediate‐to‐high‐risk patients initiating chemotherapy. However, the efficacy and safety of apixaban according to baseline chemotherapy class remain incompletely characterized. Methods: We conducted a post hoc analysis stratified by chemotherapy class of the randomized, double‐blind, placebo‐controlled AVERT trial comparing apixaban (2.5 mg twice daily) with placebo in ambulatory cancer patients initiating chemotherapy. The primary efficacy outcome was VTE, and the primary safety outcome was clinically relevant bleeding (major or clinically relevant non major bleeding (CRNMB)) per ISTH criteria. A subgroup analysis compared platinum‐based with non‐platinum chemotherapy. Cox proportional hazards models estimated hazard ratios (HRs) and 95% confidence intervals (CI), adjusted for age, sex, and study site. Treatment‐by‐platinum interaction terms were used to assess effect modification by platinum exposure. Results: A total of 563 patients were included and categorized by one or more chemotherapy classes at randomization. Compared with placebo, apixaban appeared to reduce VTE in patients on platinum (HR 0.30, 95% CI 0.16–0.57), taxane (HR 0.42, 95% CI 0.23–0.75), taxane‐platinum (HR 0.28, 95% CI 0.12–0.68), topoisomerase inhibitor (HR 0.32, 95% CI 0.19–0.53), and antimetabolite regimens (HR 0.25, 95% CI 0.12–0.54), without increased bleeding. Among placebo‐treated patients, platinum‐based chemotherapy was associated with a higher risk of VTE compared with non‐platinum regimens (HR 2.25, 95% CI 1.48–3.42), whereas no statistically significant difference was observed among apixaban‐treated patients. Treatment‐by‐platinum interaction testing did not demonstrate significant effect modification by platinum exposure. Conclusion: In this exploratory, hypothesis‐generating analysis, apixaban thromboprophylaxis was associated with reduced VTE across several chemotherapy regimens with generally acceptable safety outcomes. Patients receiving platinum‐based chemotherapy may derive greater absolute benefit from thromboprophylaxis in the setting of higher underlying thrombotic risk.
- 25 October 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (11)
Open AccessEfficacy and Safety of Apixaban Thromboprophylaxis According to Baseline Chemotherapy Class in High‐Risk Ambulatory Cancer Patients: A Post Hoc Analysis of the AVERT Trial
Background: Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in cancer patients. The AVERT trial showed apixaban thromboprophylaxis reduced VTE in intermediate‐to‐high‐risk patients initiating chemotherapy. However, the efficacy and safety of apixaban according to baseline chemotherapy class remain incompletely characterized. Methods: We conducted a post hoc analysis stratified by chemotherapy class of the randomized, double‐blind, placebo‐controlled AVERT trial comparing apixaban (2.5 mg twice daily) with placebo in ambulatory cancer patients initiating chemotherapy. The primary efficacy outcome was VTE, and the primary safety outcome was clinically relevant bleeding (major or clinically relevant non major bleeding (CRNMB)) per ISTH criteria. A subgroup analysis compared platinum‐based with non‐platinum chemotherapy. Cox proportional hazards models estimated hazard ratios (HRs) and 95% confidence intervals (CI), adjusted for age, sex, and study site. Treatment‐by‐platinum interaction terms were used to assess effect modification by platinum exposure. Results: A total of 563 patients were included and categorized by one or more chemotherapy classes at randomization. Compared with placebo, apixaban appeared to reduce VTE in patients on platinum (HR 0.30, 95% CI 0.16–0.57), taxane (HR 0.42, 95% CI 0.23–0.75), taxane‐platinum (HR 0.28, 95% CI 0.12–0.68), topoisomerase inhibitor (HR 0.32, 95% CI 0.19–0.53), and antimetabolite regimens (HR 0.25, 95% CI 0.12–0.54), without increased bleeding. Among placebo‐treated patients, platinum‐based chemotherapy was associated with a higher risk of VTE compared with non‐platinum regimens (HR 2.25, 95% CI 1.48–3.42), whereas no statistically significant difference was observed among apixaban‐treated patients. Treatment‐by‐platinum interaction testing did not demonstrate significant effect modification by platinum exposure. Conclusion: In this exploratory, hypothesis‐generating analysis, apixaban thromboprophylaxis was associated with reduced VTE across several chemotherapy regimens with generally acceptable safety outcomes. Patients receiving platinum‐based chemotherapy may derive greater absolute benefit from thromboprophylaxis in the setting of higher underlying thrombotic risk.
- 17 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (854) , eadu7160
Plasma proteomics improves thrombosis prediction in patients with cancer and identifies targetable IL-17–driven endothelial activation
Thrombosis remains a major cause of morbidity and mortality in patients with cancer. Existing risk models fail to reliably predict venous thromboembolism (VTE), underscoring the need for more accurate predictive models. In this study, we conducted a high-throughput proteomic analysis of 1105 plasma proteins in peripheral blood samples from patients with newly diagnosed lung or gastric cancer who were prospectively monitored for VTE development. Using a Bayesian probabilistic machine learning approach, we developed a predictive model incorporating 11 protein biomarkers and five clinical parameters (age, sex, history of VTE, body mass index, and hemoglobin), which outperformed the standardly used Khorana prediction score [ c statistic 0.84 (0.79 to 0.90) as compared with 0.36 (0.27 to 0.45)]. Orthogonal validation in an external placebo cohort from a phase 3 trial confirmed the model’s predictive power. Further investigation into the mechanistic role of CD200 receptor 1 (CD200R1), an immune checkpoint receptor known to limit leukocyte inflammatory response that contributed strongly to the model, showed that reduced concentrations in plasma correlated with higher D-dimer concentrations and thrombosis risk. CD200R1-deficient mice were characterized by features of a prothrombotic state, with elevated thrombin-antithrombin complexes, increased interleukin-17A (IL-17A), and endothelial inflammation. Administration of anti–IL-17A antibodies to CD200R1-deficient mice normalized thrombin-antithrombin complexes in vivo, and a meta-analysis of human COVID-19 studies showed reduced pulmonary thromboembolism in those on anti–IL-17A antibodies. These findings highlight the utility of plasma proteomics to improve prediction of thrombosis in patients with cancer and to identify unanticipated mechanistic insights and therapeutic targets in thrombo-inflammatory disease.
- 17 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (854) , eadu7160
Plasma proteomics improves thrombosis prediction in patients with cancer and identifies targetable IL-17–driven endothelial activation
Thrombosis remains a major cause of morbidity and mortality in patients with cancer. Existing risk models fail to reliably predict venous thromboembolism (VTE), underscoring the need for more accurate predictive models. In this study, we conducted a high-throughput proteomic analysis of 1105 plasma proteins in peripheral blood samples from patients with newly diagnosed lung or gastric cancer who were prospectively monitored for VTE development. Using a Bayesian probabilistic machine learning approach, we developed a predictive model incorporating 11 protein biomarkers and five clinical parameters (age, sex, history of VTE, body mass index, and hemoglobin), which outperformed the standardly used Khorana prediction score [ c statistic 0.84 (0.79 to 0.90) as compared with 0.36 (0.27 to 0.45)]. Orthogonal validation in an external placebo cohort from a phase 3 trial confirmed the model’s predictive power. Further investigation into the mechanistic role of CD200 receptor 1 (CD200R1), an immune checkpoint receptor known to limit leukocyte inflammatory response that contributed strongly to the model, showed that reduced concentrations in plasma correlated with higher D-dimer concentrations and thrombosis risk. CD200R1-deficient mice were characterized by features of a prothrombotic state, with elevated thrombin-antithrombin complexes, increased interleukin-17A (IL-17A), and endothelial inflammation. Administration of anti–IL-17A antibodies to CD200R1-deficient mice normalized thrombin-antithrombin complexes in vivo, and a meta-analysis of human COVID-19 studies showed reduced pulmonary thromboembolism in those on anti–IL-17A antibodies. These findings highlight the utility of plasma proteomics to improve prediction of thrombosis in patients with cancer and to identify unanticipated mechanistic insights and therapeutic targets in thrombo-inflammatory disease.
- Open Access
- 8 May 2026
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 24 (8) , 2923-2936
Development of models for predicting the 7-month risk of venous thromboembolism and clinically relevant bleeding in ambulatory patients with cancer: analysis from the apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients trial
- 8 May 2026
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 24 (8) , 2923-2936
Open AccessDevelopment of models for predicting the 7-month risk of venous thromboembolism and clinically relevant bleeding in ambulatory patients with cancer: analysis from the apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients trial
- Open Access
- 16 April 2026
- Published by PAGEPress Publications in Bleeding, Thrombosis and Vascular Biology
- Vol. 5 (s1)
Cancer-associated superficial vein thrombosis: clinical outcomes and management
Venous thromboembolism (VTE) is a major cause of morbidity and noncancer mortality in patients with active malignancy, and management frameworks for cancer-associated deep vein thrombosis (DVT) and pulmonary embolism (PE) are well developed. In contrast, there exists controversy in the management of isolated superficial vein thrombosis (iSVT) in patients with active malignancies, as the guideline recommended treatment regimens for iSVT are based on randomized trials that largely excluded patients with active cancer, Furthermore, patients with cancer have a higher risk of bleeding and thrombosis complicating anticoagulant management. This review synthesizes evidence on outcomes and management of cancer-associated iSVT. The evidence indicates there is a high rate of subsequent VTE incidence after cancer-associated iSVT despite anticoagulation, and comparisons of patients with active malignancy to noncancer- associated iSVT demonstrated a substantially higher VTE risk with cancer, with low rates of major bleeding. This suggests that patients with cancer-associated iSVT may benefit from higher doses of anticoagulation and/or extended therapy. However, the data suffers from heterogeneity and limited numbers emphasizing the need for randomized controlled trials to assess the optimal anticoagulant intensity/duration for patients with cancer-associated iSVT.
- 16 April 2026
- Published by PAGEPress Publications in Bleeding, Thrombosis and Vascular Biology
- Vol. 5 (s1)
Open AccessCancer-associated superficial vein thrombosis: clinical outcomes and management
Venous thromboembolism (VTE) is a major cause of morbidity and noncancer mortality in patients with active malignancy, and management frameworks for cancer-associated deep vein thrombosis (DVT) and pulmonary embolism (PE) are well developed. In contrast, there exists controversy in the management of isolated superficial vein thrombosis (iSVT) in patients with active malignancies, as the guideline recommended treatment regimens for iSVT are based on randomized trials that largely excluded patients with active cancer, Furthermore, patients with cancer have a higher risk of bleeding and thrombosis complicating anticoagulant management. This review synthesizes evidence on outcomes and management of cancer-associated iSVT. The evidence indicates there is a high rate of subsequent VTE incidence after cancer-associated iSVT despite anticoagulation, and comparisons of patients with active malignancy to noncancer- associated iSVT demonstrated a substantially higher VTE risk with cancer, with low rates of major bleeding. This suggests that patients with cancer-associated iSVT may benefit from higher doses of anticoagulation and/or extended therapy. However, the data suffers from heterogeneity and limited numbers emphasizing the need for randomized controlled trials to assess the optimal anticoagulant intensity/duration for patients with cancer-associated iSVT.
- Open Access
- 12 December 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (16) , 1933-1945
Venous thromboembolism and bleeding in cancer patients: role of inflammatory and cardiac biomarkers
Background and Aims: Patients with cancer have increased risk of venous thromboembolism (VTE) and bleeding. Inflammatory and cardiac biomarkers may predict these complications, but their role remains unclear. This study examined associations between two inflammatory-related markers (C-reactive protein and growth differentiation factor-15) and two cardiac markers [N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T (hs-TnT)] with VTE and clinically relevant bleeding in cancer patients. Methods: A post hoc analysis of the AVERT trial, which evaluated apixaban for VTE prevention in ambulatory cancer patients with a Khorana score of ≥2, was performed. Biomarkers were measured at baseline and 1 month, with C-reactive protein also at 3 months. Fine and Gray regression, accounting for competing risk of death and adjusted for age and advanced cancer, estimated subdistribution hazard ratios (SHRs) for VTE and clinically relevant bleeding. Results: Of 574 patients, 514 provided baseline samples. One- and 3-month samples were available from 454 and 447, and 378 and 364, patients without prior VTE and bleeding events, respectively. Elevated baseline growth differentiation factor-15 was associated with increased VTE risk [SHR 1.36, 95% confidence interval (CI) 1.01–1.84]. N-terminal pro-B-type natriuretic peptide (SHR 1.44, 95% CI 1.08–1.92) and C-reactive protein (SHR 1.38, 95% CI 1.07–1.76) were linked to bleeding risk. Increasing high-sensitivity troponin T from baseline to 1 month was associated with higher VTE risk (SHR 1.89, 95% CI 1.14–3.16). Nomograms were developed to estimate VTE and clinically relevant bleeding risks. Conclusions: Select inflammatory-related and cardiac markers were associated with VTE and bleeding risks in cancer patients, which can be determined using developed nomograms. Prospective research is needed to confirm these findings.
- 12 December 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (16) , 1933-1945
Open AccessVenous thromboembolism and bleeding in cancer patients: role of inflammatory and cardiac biomarkers
Background and Aims: Patients with cancer have increased risk of venous thromboembolism (VTE) and bleeding. Inflammatory and cardiac biomarkers may predict these complications, but their role remains unclear. This study examined associations between two inflammatory-related markers (C-reactive protein and growth differentiation factor-15) and two cardiac markers [N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T (hs-TnT)] with VTE and clinically relevant bleeding in cancer patients. Methods: A post hoc analysis of the AVERT trial, which evaluated apixaban for VTE prevention in ambulatory cancer patients with a Khorana score of ≥2, was performed. Biomarkers were measured at baseline and 1 month, with C-reactive protein also at 3 months. Fine and Gray regression, accounting for competing risk of death and adjusted for age and advanced cancer, estimated subdistribution hazard ratios (SHRs) for VTE and clinically relevant bleeding. Results: Of 574 patients, 514 provided baseline samples. One- and 3-month samples were available from 454 and 447, and 378 and 364, patients without prior VTE and bleeding events, respectively. Elevated baseline growth differentiation factor-15 was associated with increased VTE risk [SHR 1.36, 95% confidence interval (CI) 1.01–1.84]. N-terminal pro-B-type natriuretic peptide (SHR 1.44, 95% CI 1.08–1.92) and C-reactive protein (SHR 1.38, 95% CI 1.07–1.76) were linked to bleeding risk. Increasing high-sensitivity troponin T from baseline to 1 month was associated with higher VTE risk (SHR 1.89, 95% CI 1.14–3.16). Nomograms were developed to estimate VTE and clinically relevant bleeding risks. Conclusions: Select inflammatory-related and cardiac markers were associated with VTE and bleeding risks in cancer patients, which can be determined using developed nomograms. Prospective research is needed to confirm these findings.
- 19 April 2024
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 22 (7) , 1997-2008
A deep-learning approach to predict bleeding risk over time in patients on extended anticoagulation therapy
- 19 April 2024
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 22 (7) , 1997-2008
A deep-learning approach to predict bleeding risk over time in patients on extended anticoagulation therapy
- Open Access
- 3 April 2024
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 8 (3) , 102403
Machine learning analysis of bleeding status in venous thromboembolism patients
- 3 April 2024
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 8 (3) , 102403
Open AccessMachine learning analysis of bleeding status in venous thromboembolism patients
- 15 March 2024
- Published by Oxford University Press (OUP) in Academic Medicine
- Vol. 99 (7) , 736-740
Quality and Patient Safety Metrics: Developing a Structured Program for Improving Patient Care in the Department of Medicine at The Ottawa Hospital
Problem: Despite increasing recognition of the importance of quality and patient safety in academic medicine, challenges remain with ensuring physician participation in quality assurance and quality improvement efforts, such as lack of compensation and enabling resources. An organizational culture that includes physician leadership and a supportive infrastructure is needed to encourage physician backing of quality and patient safety initiatives. Approach: The authors describe the development of a robust quality and patient safety program in the Department of Medicine at The Ottawa Hospital over the past 7 years and highlight how the department changed its organizational culture by prioritizing quality and patient safety and establishing the necessary infrastructure to support this program. Program development was characterized by 4 overarching themes: incentives, administrative structure and physician leadership, training and support, and system enhancements. Outcomes: As a result of the program, the department broadly implemented a standardized framework for conducting quality committee meetings and morbidity and mortality rounds and reviewing patient safety incidents and patient experience across its 16 divisions. This has led to 100% departmental compliance on corporate quality assurance metrics each year (e.g., regular multidisciplinary divisional quality committee meetings), along with physician participation in formal quality improvement initiatives that align with larger corporate goals. Next Steps: The authors reflect on lessons learned during the implementation of the program and the essential elements that contributed to its success. Next steps for the program include using a centralized repository of quality and patient safety data, including patient safety incident dashboards, to encourage greater divisional collaboration on quality improvement initiatives and continuous institutional learning over time. Another important avenue will be to create an academic hub for excellence in quality and a formal approach to reward and promote physicians for their quality work.
- 15 March 2024
- Published by Oxford University Press (OUP) in Academic Medicine
- Vol. 99 (7) , 736-740
Quality and Patient Safety Metrics: Developing a Structured Program for Improving Patient Care in the Department of Medicine at The Ottawa Hospital
Problem: Despite increasing recognition of the importance of quality and patient safety in academic medicine, challenges remain with ensuring physician participation in quality assurance and quality improvement efforts, such as lack of compensation and enabling resources. An organizational culture that includes physician leadership and a supportive infrastructure is needed to encourage physician backing of quality and patient safety initiatives. Approach: The authors describe the development of a robust quality and patient safety program in the Department of Medicine at The Ottawa Hospital over the past 7 years and highlight how the department changed its organizational culture by prioritizing quality and patient safety and establishing the necessary infrastructure to support this program. Program development was characterized by 4 overarching themes: incentives, administrative structure and physician leadership, training and support, and system enhancements. Outcomes: As a result of the program, the department broadly implemented a standardized framework for conducting quality committee meetings and morbidity and mortality rounds and reviewing patient safety incidents and patient experience across its 16 divisions. This has led to 100% departmental compliance on corporate quality assurance metrics each year (e.g., regular multidisciplinary divisional quality committee meetings), along with physician participation in formal quality improvement initiatives that align with larger corporate goals. Next Steps: The authors reflect on lessons learned during the implementation of the program and the essential elements that contributed to its success. Next steps for the program include using a centralized repository of quality and patient safety data, including patient safety incident dashboards, to encourage greater divisional collaboration on quality improvement initiatives and continuous institutional learning over time. Another important avenue will be to create an academic hub for excellence in quality and a formal approach to reward and promote physicians for their quality work.
- Top Cited PapersOpen Access
Antithrombotic Therapy for VTE Disease
- Open Access
Standardized Data Elements for Patients with Acute Pulmonary Embolism: A Consensus Report from the Pulmonary Embolism Research Collaborative
Recent advances in therapy and the promulgation of multidisciplinary pulmonary embolism teams (PERTs) show great promise to improve management and outcomes of acute pulmonary embolism (PE). However, the absence of randomized evidence and lack of consensus leads to tremendous variations in treatment and compromises the wide implementation of new innovations. Moreover, the changing landscape of healthcare, where quality, cost, and accountability are increasingly relevant, dictates that a broad spectrum of outcomes of care must be routinely monitored to fully capture the impact of modern PE treatment. We set out to standardize data collection in PE patients undergoing evaluation and treatment, and thus establish the foundation for an expanding evidence base that will address gaps in evidence and inform future care for acute PE. To do so, over 100 international PE thought leaders convened in Washington, DC in April 2022 to form the Pulmonary Embolism Research Collaborative (PERC™). Participants included physician experts, key members of the United States Food and Drug Administration (FDA), patient representatives, and industry leaders. Recognizing the multi-disciplinary nature of PE care, the Pulmonary Embolism Research Collaborative (PERC™) was created with representative experts from stakeholder medical subspecialties, including cardiology, pulmonology, vascular medicine, critical care, hematology, cardiac surgery, emergency medicine, hospital medicine, and pharmacology. A list of critical evidence gaps was composed with a matching comprehensive set of standardized data elements; these data points will provide a foundation for productive research, knowledge enhancement, and advancement of clinical care within the field of acute PE, and contribute to answering urgent unmet needs in PE management. Evidence produced through PERC™, as it is applied to data collection, promises to provide crucial knowledge that will ultimately produce a robust evidence base that will lead to standardization and harmonization of PE management and improved outcomes. CLINICAL PERSPECTIVE: 1) What is new?: Recent advances have increased options for treatment of acute pulmonary embolism, yet there remain wide variations in management due to the lack of a reliable evidence base upon which to base therapeutic decisions. The PERT Consortium TM is a strong advocate of evidence based care for PE patients and therefore initiated the Pulmonary Embolism Research Collaborative (PERC TM ) to establish a foundation for advancing high quality research and improving clinical care. A novel comprehensive set of standardized data elements is proposed for collection in patients with acute pulmonary embolism, to provide a foundation for expanding the evidence base and enhancing care. 2) What are the clinical implications?: Standardizing collection of data for acute pulmonary embolism will enable analyses that will inform optimal risk stratification, treatment, and follow-up of patients with pulmonary embolism, and provide evidence-based treatment algorithms that will improve outcomes. Registries created using the proposed standardized elements will enable benchmarking and quality assurance for clinicians caring for pulmonary embolism patients. Incorporation of comprehensive standardized data elements into FDA IDE trials will enable the Agency to better assess the safety and effectiveness of investigational devices.
Open AccessStandardized Data Elements for Patients with Acute Pulmonary Embolism: A Consensus Report from the Pulmonary Embolism Research Collaborative
Recent advances in therapy and the promulgation of multidisciplinary pulmonary embolism teams (PERTs) show great promise to improve management and outcomes of acute pulmonary embolism (PE). However, the absence of randomized evidence and lack of consensus leads to tremendous variations in treatment and compromises the wide implementation of new innovations. Moreover, the changing landscape of healthcare, where quality, cost, and accountability are increasingly relevant, dictates that a broad spectrum of outcomes of care must be routinely monitored to fully capture the impact of modern PE treatment. We set out to standardize data collection in PE patients undergoing evaluation and treatment, and thus establish the foundation for an expanding evidence base that will address gaps in evidence and inform future care for acute PE. To do so, over 100 international PE thought leaders convened in Washington, DC in April 2022 to form the Pulmonary Embolism Research Collaborative (PERC™). Participants included physician experts, key members of the United States Food and Drug Administration (FDA), patient representatives, and industry leaders. Recognizing the multi-disciplinary nature of PE care, the Pulmonary Embolism Research Collaborative (PERC™) was created with representative experts from stakeholder medical subspecialties, including cardiology, pulmonology, vascular medicine, critical care, hematology, cardiac surgery, emergency medicine, hospital medicine, and pharmacology. A list of critical evidence gaps was composed with a matching comprehensive set of standardized data elements; these data points will provide a foundation for productive research, knowledge enhancement, and advancement of clinical care within the field of acute PE, and contribute to answering urgent unmet needs in PE management. Evidence produced through PERC™, as it is applied to data collection, promises to provide crucial knowledge that will ultimately produce a robust evidence base that will lead to standardization and harmonization of PE management and improved outcomes. CLINICAL PERSPECTIVE: 1) What is new?: Recent advances have increased options for treatment of acute pulmonary embolism, yet there remain wide variations in management due to the lack of a reliable evidence base upon which to base therapeutic decisions. The PERT Consortium TM is a strong advocate of evidence based care for PE patients and therefore initiated the Pulmonary Embolism Research Collaborative (PERC TM ) to establish a foundation for advancing high quality research and improving clinical care. A novel comprehensive set of standardized data elements is proposed for collection in patients with acute pulmonary embolism, to provide a foundation for expanding the evidence base and enhancing care. 2) What are the clinical implications?: Standardizing collection of data for acute pulmonary embolism will enable analyses that will inform optimal risk stratification, treatment, and follow-up of patients with pulmonary embolism, and provide evidence-based treatment algorithms that will improve outcomes. Registries created using the proposed standardized elements will enable benchmarking and quality assurance for clinicians caring for pulmonary embolism patients. Incorporation of comprehensive standardized data elements into FDA IDE trials will enable the Agency to better assess the safety and effectiveness of investigational devices.